Long-term efficacy and safety of single-dose omalizumab in treating acute spontaneous urticaria

Acute spontaneous urticaria has a high incidence, with sudden and severe symptoms that can significantly impact daily life and work. If not properly managed, it may lead to severe reactions such as angioedema, gastrointestinal symptoms, or even anaphylactic shock. Research on acute spontaneous urticaria is limited, with unclear etiology, and treatment largely relies on antihistamines and corticosteroids, which may not prevent progression to chronic urticaria. In this study, three patients with acute spontaneous urticaria, unresponsive to conventional treatments, chose a single 300mg subcutaneous injection of Omalizumab after evaluating the risks and benefits. Within 1-3 days, all patients showed significant symptom improvement, with near-complete resolution of lesions. Within a week, they resumed normal daily activities, and no recurrence was observed during 12 months of follow-up, with no adverse reactions. This study demonstrates the efficacy and safety of Omalizumab for acute spontaneous urticaria, particularly in cases resistant to antihistamines and corticosteroids. Early administration of Omalizumab can effectively control disease progression, reduce impact on daily life, and may lower the risk of developing chronic urticaria. These findings suggest that Omalizumab should be considered a valuable option in treating acute spontaneous urticaria, especially when conventional therapies fail, offering rapid symptom relief and long-term disease control.